Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy

Bibliography

• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365(9455):217-23
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266
   PubMed Web of Science ®Google Scholar
• Arauz-Pacheco C, Parrott MA, Raskin P, American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26(Suppl 1):S80-2
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289(19):2560-72
   PubMed Web of Science ®Google Scholar
• Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. blood pressure lowering treatment trialists' collaboration. Lancet 2000;356(9246):1955-64
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903-13
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the american heart association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation 2007;115(21):2761-88
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022-31
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349(20):1893-906
   PubMed Web of Science ®Google Scholar
• Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289(19):2534-44
   PubMed Web of Science ®Google Scholar
• Trenkwalder P. Combination therapy with AT(1)-receptor blockers. J Hum Hypertens 2002;16(Suppl 3):S17-25
   PubMedGoogle Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288(23):2981-97
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the study on cognition and prognosis in the elderly (SCOPE). J Am Coll Cardiol 2004;44(6):1175-80
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163(13):1555-65
   PubMed Web of Science ®Google Scholar
• Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004;110(17):2618-26
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345(23):1667-75
   PubMed Web of Science ®Google Scholar
• Diovan HCT (prescribing information). East Hanover (NJ): Novartis Pharmaceuticals Corp 2008
   Google Scholar
• Langtry HD, McClellan KJ. Valsartan/hydrochlorothiazide. Drugs 1999;57(5):751-5; discussion 756-8
   PubMed Web of Science ®Google Scholar
• Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997;52(2):115-20
   PubMed Web of Science ®Google Scholar
• Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977;12(4):297-303
   PubMed Web of Science ®Google Scholar
• Weir SJ, Dimmitt DC, Lanman RC, et al. Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. Biopharm Drug Dispos 1998;19(6):365-71
   PubMed Web of Science ®Google Scholar
• Jackson EK. Chapter 28. diuretics. In: Brunton LL, Lazo JS, Parker KL, editors, Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th edition. New York: The McGraw-Hill Companies, Inc.; 2006
   Google Scholar
• Sioufi A, Marfil F, Jaouen A, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos 1998;19(4):237-44
   PubMed Web of Science ®Google Scholar
• Prasad P, Mangat S, Choi L, et al. Effect of renal function on the pharmacokinetics of valsartan. Clin Drug Investig 1997;13(4):207-14
   Web of Science ®Google Scholar
• Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998;12(12):861-6
   PubMed Web of Science ®Google Scholar
• Jordan J, Engeli S, Boschmann M, et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens 2005;23(12):2313-8
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, et al; ONTARGET Investigators, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59
   PubMed Web of Science ®Google Scholar
• Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007;29(1):61-73
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: An 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005;27(7):1013-21
   PubMed Web of Science ®Google Scholar
• Schmidt A, Adam SA, Kolloch R, et al. Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. Blood Press 2001;10(4):230-7
   PubMed Web of Science ®Google Scholar
• Bobrie G, Delonca J, Moulin C, et al. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005;18(11):1482-8
   PubMed Web of Science ®Google Scholar
• Palatini P, Malacco E, Fogari R, et al. A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. J Hypertens 2001;19(9):1691-6
   PubMed Web of Science ®Google Scholar
• Waeber B, Aschwanden R, Sadecky L, Ferber P. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. J Hypertens 2001;19(11):2097-104
   PubMed Web of Science ®Google Scholar
• White WB, Murwin D, Chrysant SG, et al. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Press Monit 2008;13(1):21-7
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Wright JT Jr, Samuel R, et al. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. Blood Press Monit 2009;14(3):112-20
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Glazer RD, Pettyjohn FS, et al. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin 2008;24(8):2303-11
   PubMed Web of Science ®Google Scholar
• White WB, Calhoun DA, Samuel R, et al. Improving blood pressure control: Increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (val-DICTATE) trial. J Clin Hypertens (Greenwich) 2008;10(6):450-8
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Tykarski A, Baumgart P, et al. Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. Blood Press Suppl 2008;1:15-23
   PubMedGoogle Scholar
• Sharma AM, Davidson J, Koval S, Lacourciere Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: The SMOOTH study. Cardiovasc Diabetol 2007;6:28
   PubMed Web of Science ®Google Scholar
• Weir MR, Ferdinand KC, Flack JM, et al. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension 2005;46(3):508-13
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005;27(5):578-87
   PubMed Web of Science ®Google Scholar
• Malacco E, Vari N, Capuano V, et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the val-syst study. Clin Ther 2003;25(11):2765-80
   PubMed Web of Science ®Google Scholar
• Everett BM, Glynn RJ, Danielson E, Ridker PM, Val-MARC Investigators. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: A prespecified subgroup analysis of a community-based, randomized, open-label trial. Clin Ther 2008;30(4):661-72
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Rifai N, Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: Primary report of the val-MARC trial. Hypertension 2006;48(1):73-9
   PubMed Web of Science ®Google Scholar
• Conen D, Everett BM, Glynn RJ, Ridker PM. Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the val-MARC trial. Heart 2008;94(3):e13
   PubMed Web of Science ®Google Scholar
• Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: Results from the health survey for england 1998. Hypertension 2001;38(4):827-32
   PubMed Web of Science ®Google Scholar
• EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II euro heart survey programme. Eur Heart J 2001;22(7):554-72
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. HOT study group. Lancet 1998;351(9118):1755-62
   PubMed Web of Science ®Google Scholar
• Trenkwalder P. AT1-receptor blocker-based combination therapy in hypertension. Blood Pressure 2001;10(Suppl 3):18-25
   Web of Science ®Google Scholar
• Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42(6):1137-43
   PubMed Web of Science ®Google Scholar
• Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15(12):3126-33
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370(9583):221-9
   PubMed Web of Science ®Google Scholar
• Exforge HCT (prescribing information). East Hanover (NJ): Novartis Pharmaceutical Corporation 2009
   Google Scholar